Tarsus Pharmaceuticals
TARS
73.01
-4.66
-6.00%
Tarsus Pharmaceuticals
US · TARS
#2389 by market cap
Listed 2020
73.01
-4.66
-6.00%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $97Market Newswire · 2026/11/6
-
Rating change
William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy RatingMarket Newswire · 2026/8/12
-
Rating change
Jefferies Initiates Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Announces Target Price $105Market Newswire · 2026/9/9
-
Rating change
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100Market Newswire · 2026/8/12
-
Rating change
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $104Market Newswire · 2026/8/7
-
Rating change
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $98Market Newswire · 2026/8/4
-
A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $97 to $106Market Newswire · 2026/11/5
-
Rating change
BofA Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $84Market Newswire · 2026/10/12
-
Rating change
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $94Market Newswire · 2026/10/29
-
Rating change
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100Market Newswire · 2026/8/12
-
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $110Market Newswire · 2026/11/11
-
Rating change
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $110Market Newswire · 2026/9/17
-
Company notice
SHOUCHENG: VOLUNTARY ANNOUNCEMENT - REGARDING THE INVESTMENT IN TARSHKEX · 2026/4/16
-
Rating change
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100Market Newswire · 2026/8/7
-
Earnings Flash (TARS) Tarsus Pharmaceuticals Posts Q3 Loss $14.40, Vs. FactSet Est of $1.46 LossMT Newswires · 2026/11/4
-
Rating change
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $104Market Newswire · 2026/8/8
-
Rating change
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100Market Newswire · 2026/10/2
-
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $102Market Newswire · 2026/11/6
-
Rating change
H.C. Wainwright Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $88Market Newswire · 2026/8/7
-
Rating change
Goldman Sachs Upgrades Tarsus Pharmaceuticals(TARS.US) to Buy Rating, Raises Target Price to $116Market Newswire · 2026/9/24
-
Rating change
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $89Market Newswire · 2026/7/22
-
Rating change
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $97Market Newswire · 2026/7/22
-
Rating change
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $98Market Newswire · 2026/7/31
-
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $110Market Newswire · 2026/10/12
-
Rating change
Oppenheimer Initiates Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Announces Target Price $97Market Newswire · 2026/7/14
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.
Tarsus Pharmaceuticals discussion 0 comments